Core Insights - NeOnc Technologies Holdings, Inc. has been included in the Russell Microcap® Index, which is a significant recognition of the company's growth and commitment to shareholder value [1][3] - The Russell Microcap® Index includes companies with an average market capitalization of approximately $640 million, covering stocks ranging from about $30 million to $3 billion [3][4] - NeOnc is focused on advancing its Phase II clinical trials for CNS cancers and expanding into the MENA region through a proposed partnership with Quazar [3] Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system cancers and disorders [1][6] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates with patent protections extending to 2038 [6] - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] Industry Context - The Russell US Indexes reconstitution ranks the 4,000 largest US stocks by total market capitalization, and membership in the Russell Microcap® Index is valid for one year [2][4] - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [4]

Core Insights - Palisade Bio, Inc. has appointed Emil Chuang, MB BS FRACP to its Board of Directors, enhancing its clinical strategy in treating Fibrostenotic Crohn's Disease and Ulcerative Colitis [1][9] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [10] Leadership Experience - Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience, including contributions to drug development programs that led to two successful regulatory approvals: infliximab for pediatric Crohn's disease and lorcaserin for morbid obesity [3][4] - His previous roles include Chief Medical Officer at Intrinsic Medicine and leadership positions at Nestlé Health Science, Takeda, and Progenity, with over 80 peer-reviewed publications to his name [6][7] Strategic Importance - The addition of Dr. Chuang is expected to provide valuable insights into the company's clinical programs, particularly in inflammatory bowel diseases [5][6] - The company aims to leverage Dr. Chuang's expertise to advance its pipeline and address unmet medical needs in the therapeutic landscape [6]

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to combine Salarius' drug candidates with Decoy's IMPACT™ platform, which focuses on developing therapeutics for respiratory viruses and cancer [3][10] - The combined company will be led by Decoy's executive team, including CEO Frederick "Rick" Pierce and CSO Barbara Hibner [4] Research Insights - Two recent animal studies highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies published in peer-reviewed journals provide insights into the role of KDM1A in regulating neural stem cells and oral squamous cell carcinoma progression [5] Future Plans - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6] - The ongoing clinical trial at MDACC may yield data on MDS and CMML patients who have previously failed or relapsed after hypomethylating agent therapy [7]

Core Insights - Candel Therapeutics, Inc. has been added to multiple Russell indexes as part of the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025, which reflects the company's progress in clinical programs and discovery efforts in cancer immunotherapy [1][2][3] Company Overview - Candel is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to elicit systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] Clinical Development - Candel's lead product candidate, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [5] - A pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer is ongoing under a Special Protocol Assessment (SPA) with the FDA [5] - CAN-2409 has received Fast Track Designation from the FDA for multiple indications, including treatment-resistant PDAC and localized prostate cancer [5] Strategic Importance of Index Inclusion - Inclusion in the Russell Value indexes is expected to enhance Candel's engagement with the investment community and support its pre-commercialization efforts for CAN-2409 [3] - Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them [3] Future Prospects - The company is preparing for a potential submission of a Biologics License Application for CAN-2409 and continues to advance its innovative immunotherapy platform across various solid tumors [3] - Candel's enLIGHTEN™ Discovery Platform aims to leverage human biology and advanced analytics to create new viral immunotherapies for solid tumors [6]

-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the completion of patient ...

REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic's leading AI models. In this ...

"We're excited to welcome Sergio to the DIMERx team," said Nikhilesh Singh, MPharm, PhD, Chief Executive Officer. "His deep operational expertise, strategic insight, and capital markets experience come at a critical time in our evolution. With support from the NIH HEAL Initiative and strong momentum in our clinical programs, DIMERx is entering a new phase of growth. Sergio's track record guiding biopharma companies through development and fundraising will be instrumental as we advance our mission to deliver ...

WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place July 17-18 in ...

Core Insights - Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, showing significant BMI reductions in patients with acquired hypothalamic obesity [2][3] - The company plans to engage with regulatory authorities for a Phase 3 trial design and has requested an End-of-Phase 2 meeting with the U.S. FDA [7] Group 1: Trial Results - Bivamelagon achieved BMI reductions of -9.3% in the 600mg cohort and -7.7% in the 400mg cohort at 14 weeks [1][4] - A post-hoc analysis indicated that the BMI reductions from bivamelagon were consistent with those achieved by setmelanotide in similar patient populations [3][5] - Patients reported a mean reduction of -2.8 points in hunger scores in both the 600mg and 400mg cohorts [1][3] Group 2: Safety and Tolerability - The trial demonstrated safety and tolerability consistent with MC4R agonism, with limited instances of localized hyperpigmentation observed [4][6] - The most common adverse events included mild diarrhea and nausea, with one serious adverse event reported [6] Group 3: Next Steps and Regulatory Plans - Rhythm plans to seek input from U.S. and EU regulatory authorities regarding the Phase 3 trial design for bivamelagon [7] - The company is refining the formulation of bivamelagon to potentially improve tolerability before initiating the Phase 3 trial [7] Group 4: Company Background - Rhythm Pharmaceuticals is focused on transforming the lives of patients with rare neuroendocrine diseases and has in-licensed bivamelagon from LG Chem, Ltd [2][13] - The company’s lead asset, setmelanotide, is already approved for treating certain types of obesity [13][14]

BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on Tuesday, August 5, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Br ...